Proteomika Overview

  • Founded
  • 2002
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 5
Employees
  • Latest Deal Type
  • M&A

Proteomika General Information

Description

Provider of biomarkers designed for non-invasive diagnosis of complex diseases. The company's biomarkers are diagnostic assays that offers individualized optimization of treatment regimes by measuring drug response, such as drug bioavailability and immunogenicity.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Primary Office
  • Parque Tecnológico de Bizkaia 504
  • 48160 Derio
  • Spain
+34 944 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Proteomika Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 01-Jan-2015 Completed Generating Revenue
1. Seed Round 10-Apr-2004 Completed Startup
To view Proteomika’s complete valuation and funding history, request access »

Proteomika Executive Team (3)

Name Title Board Seat Contact Info
Laureano Simón Ph.D Chief Executive Officer
Antonio Martínez Ph.D Chief Operating Officer
You’re viewing 2 of 3 executive team members. Get the full list »

Proteomika Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Proteomika Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bizkaia Seed Capital Venture Capital Minority 000 0000 000000 0
To view Proteomika’s complete investors history, request access »